{"id":20470,"date":"2025-01-03T14:55:56","date_gmt":"2025-01-03T06:55:56","guid":{"rendered":"https:\/\/flcube.com\/?p=20470"},"modified":"2025-01-03T14:55:59","modified_gmt":"2025-01-03T06:55:59","slug":"nmpa-grants-conditional-approval-for-chinas-first-mscs-therapy-for-agvhd","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=20470","title":{"rendered":"NMPA Grants Conditional Approval for China’s First MSCs Therapy for aGVHD"},"content":{"rendered":"\n

The National Medical Products Administration (NMPA) in China has conditionally approved amimestrocel from Beijing-based Platinum Life with priority review status. This mesenchymal stem cells (MSCs) therapy marks the first of its kind in China, now available for treating patients aged 14 and above with acute graft-versus-host disease (aGVHD) that primarily affects the digestive tract following the failure of hormone therapy.<\/p>\n\n\n\n

Understanding Graft-Versus-Host Disease (GVHD)<\/strong>
Graft-versus-host disease is a multi-organ syndrome that occurs post-allogeneic hematopoietic stem cell transplantation. In this condition, lymphocytes from the donor mount an attack on the recipient’s tissue. GVHD is characterized by tissue inflammation and fibrosis, affecting primarily the skin, gastrointestinal tract, liver, lungs, and mucosal surfaces.<\/p>\n\n\n\n

The Impact of Amimestrocel’s Approval<\/strong>
The conditional approval of amimestrocel by the NMPA signifies a significant advancement in the treatment options for patients suffering from aGVHD in China. This therapy offers a new approach to managing the symptoms and complications associated with this challenging post-transplant condition, potentially improving outcomes for affected individuals.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

The National Medical Products Administration (NMPA) in China has conditionally approved amimestrocel from Beijing-based Platinum…<\/p>\n","protected":false},"author":1,"featured_media":20472,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,77,3024,15],"class_list":["post-20470","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-auto-immune","tag-cell-therapy","tag-platinum-life","tag-product-approvals"],"yoast_head":"\nNMPA Grants Conditional Approval for China's First MSCs Therapy for aGVHD - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The National Medical Products Administration (NMPA) in China has conditionally approved amimestrocel from Beijing-based Platinum Life with priority review status. This mesenchymal stem cells (MSCs) therapy marks the first of its kind in China, now available for treating patients aged 14 and above with acute graft-versus-host disease (aGVHD) that primarily affects the digestive tract following the failure of hormone therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=20470\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NMPA Grants Conditional Approval for China's First MSCs Therapy for aGVHD\" \/>\n<meta property=\"og:description\" content=\"The National Medical Products Administration (NMPA) in China has conditionally approved amimestrocel from Beijing-based Platinum Life with priority review status. This mesenchymal stem cells (MSCs) therapy marks the first of its kind in China, now available for treating patients aged 14 and above with acute graft-versus-host disease (aGVHD) that primarily affects the digestive tract following the failure of hormone therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=20470\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-03T06:55:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-03T06:55:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0301.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20470#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20470\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"NMPA Grants Conditional Approval for China’s First MSCs Therapy for aGVHD\",\"datePublished\":\"2025-01-03T06:55:56+00:00\",\"dateModified\":\"2025-01-03T06:55:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20470\"},\"wordCount\":179,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20470#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0301.png\",\"keywords\":[\"Auto-immune\",\"Cell-therapy\",\"Platinum Life\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20470#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20470\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=20470\",\"name\":\"NMPA Grants Conditional Approval for China's First MSCs Therapy for aGVHD - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20470#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20470#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0301.png\",\"datePublished\":\"2025-01-03T06:55:56+00:00\",\"dateModified\":\"2025-01-03T06:55:59+00:00\",\"description\":\"The National Medical Products Administration (NMPA) in China has conditionally approved amimestrocel from Beijing-based Platinum Life with priority review status. This mesenchymal stem cells (MSCs) therapy marks the first of its kind in China, now available for treating patients aged 14 and above with acute graft-versus-host disease (aGVHD) that primarily affects the digestive tract following the failure of hormone therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20470#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=20470\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20470#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0301.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0301.png\",\"width\":1080,\"height\":720,\"caption\":\"NMPA Grants Conditional Approval for China's First MSCs Therapy for aGVHD\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=20470#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NMPA Grants Conditional Approval for China’s First MSCs Therapy for aGVHD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NMPA Grants Conditional Approval for China's First MSCs Therapy for aGVHD - Insight, China's Pharmaceutical Industry","description":"The National Medical Products Administration (NMPA) in China has conditionally approved amimestrocel from Beijing-based Platinum Life with priority review status. This mesenchymal stem cells (MSCs) therapy marks the first of its kind in China, now available for treating patients aged 14 and above with acute graft-versus-host disease (aGVHD) that primarily affects the digestive tract following the failure of hormone therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=20470","og_locale":"en_US","og_type":"article","og_title":"NMPA Grants Conditional Approval for China's First MSCs Therapy for aGVHD","og_description":"The National Medical Products Administration (NMPA) in China has conditionally approved amimestrocel from Beijing-based Platinum Life with priority review status. This mesenchymal stem cells (MSCs) therapy marks the first of its kind in China, now available for treating patients aged 14 and above with acute graft-versus-host disease (aGVHD) that primarily affects the digestive tract following the failure of hormone therapy.","og_url":"https:\/\/flcube.com\/?p=20470","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-03T06:55:56+00:00","article_modified_time":"2025-01-03T06:55:59+00:00","og_image":[{"width":1080,"height":720,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0301.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=20470#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=20470"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"NMPA Grants Conditional Approval for China’s First MSCs Therapy for aGVHD","datePublished":"2025-01-03T06:55:56+00:00","dateModified":"2025-01-03T06:55:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=20470"},"wordCount":179,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=20470#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0301.png","keywords":["Auto-immune","Cell-therapy","Platinum Life","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=20470#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=20470","url":"https:\/\/flcube.com\/?p=20470","name":"NMPA Grants Conditional Approval for China's First MSCs Therapy for aGVHD - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=20470#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=20470#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0301.png","datePublished":"2025-01-03T06:55:56+00:00","dateModified":"2025-01-03T06:55:59+00:00","description":"The National Medical Products Administration (NMPA) in China has conditionally approved amimestrocel from Beijing-based Platinum Life with priority review status. This mesenchymal stem cells (MSCs) therapy marks the first of its kind in China, now available for treating patients aged 14 and above with acute graft-versus-host disease (aGVHD) that primarily affects the digestive tract following the failure of hormone therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=20470#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=20470"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=20470#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0301.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0301.png","width":1080,"height":720,"caption":"NMPA Grants Conditional Approval for China's First MSCs Therapy for aGVHD"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=20470#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"NMPA Grants Conditional Approval for China’s First MSCs Therapy for aGVHD"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0301.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20470","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20470"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20470\/revisions"}],"predecessor-version":[{"id":20473,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/20470\/revisions\/20473"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/20472"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20470"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20470"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20470"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}